SELEPRESSIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C46H73N13O11S2
Molecular Weight	1048.2863
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O

InChI

InChIKey=JCVQBJTWWDYUFQ-MRUTUVJXSA-N

InChI=1S/C46H73N13O11S2/c1-5-26(4)38-45(69)54-30(14-9-17-35(48)60)41(65)56-32(21-36(49)61)42(66)57-33(24-72-71-23-28(47)39(63)55-31(43(67)58-38)20-27-12-7-6-8-13-27)46(70)59-19-11-16-34(59)44(68)53-29(15-10-18-51-25(2)3)40(64)52-22-37(50)62/h6-8,12-13,25-26,28-34,38,51H,5,9-11,14-24,47H2,1-4H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,52,64)(H,53,68)(H,54,69)(H,55,63)(H,56,65)(H,57,66)(H,58,67)/t26-,28-,29-,30-,31-,32-,33-,34-,38-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C46H73N13O11S2
Molecular Weight	1048.2863
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21411496 | https://www.ncbi.nlm.nih.gov/pubmed/30563433 | https://www.ncbi.nlm.nih.gov/pubmed/28807037

Selepressin (FE 202158) was designed as a selective and short-acting vasopressin type 1a receptor (V(1a)R) agonist. This drug was developed for the treatment of vasodilatory hypotension in shock. Selepressin successfully completed phase IIa clinical trial, where was found that in septic shock patients, selepressin 2.5 ng/kg/minute was able to rapidly replace norepinephrine, improve fluid balance and shorten the time of mechanical ventilation.

Originator

Approval Year

PubMed

Title	Date	PubMed
Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.	2020-04	30563433
Selepressin and Arginine Vasopressin Do Not Display Cardiovascular Risk in Atherosclerotic Rabbit.	2016	27788216
Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs.	2013-06	23429645
New, potent, selective, and short-acting peptidic V1a receptor agonists.	2011-07-14	21688787
Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.	2011-06	21411496

Sample Use Guides

In Vivo Use Guide

This was a randomized, double-blind, placebo-controlled multicenter trial in 53 patients in early septic shock (aged ≥18 years, fluid resuscitation, requiring vasopressor support) who received selepressin 1.25 ng/kg/minute (n = 10), 2.5 ng/kg/minute (n = 19), 3.75 ng/kg/minute (n = 2), or placebo (n = 21) until shock resolution or a maximum of 7 days

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:01:39 GMT 2025` Edited by `admin` on `Mon Mar 31 21:01:39 GMT 2025`
Record UNII	8P2T76M0SJ
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

SELEPRESSIN

Official Name

English

FE-202158

Preferred Name

English

SELEPRESSIN [USAN]

Common Name

English

(2-L-PHENYLALANINE,3-L-ISOLEUCINE,4-(6-OXO-L-LYSINE), 8-(5-N-(PROPAN-2-YL)-L-ORNITHINE))HUMAN VASOPRESSIN

Systematic Name

English

GLYCINAMIDE, L-CYSTEINYL-L-PHENYLALANYL-L-ISOLEUCYL-6-OXO-L-LYSYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-N5-(1-METHYLETHYL)-L-ORNITHYL-, CYCLIC (1-6)-DISULFIDE

Common Name

English

FE202158

Code

English

Selepressin [WHO-DD]

Common Name

English

selepressin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C80212